Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Immunotech Biopharm Ltd ( (HK:6978) ).
Immunotech Biopharm Ltd has announced the appointment of three new directors to its board, effective from June 26, 2025. Mr. Yang Xin and Mr. Liu Rui have been appointed as non-executive directors, while Mr. Zhang Guoguang has been appointed as an independent non-executive director. These appointments bring a wealth of experience in investment, pharmaceutical research, and legal expertise to the company, potentially strengthening its strategic direction and governance.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a company involved in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company operates with a market focus on advancing medical treatments and solutions.
Average Trading Volume: 408,300
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.54B
For a thorough assessment of 6978 stock, go to TipRanks’ Stock Analysis page.